Prognosis of Patients with Hepatocellular Carcinoma Treated with TACE: A New Score Combining Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin
Shang-Yu Lu,Han-Yao Sun,Yan Zhou,Xi Luo,Sheng Liu,Wei-Zhong Zhou,Hai-Bin Shi,Wei Yang,Wei Tian
DOI: https://doi.org/10.2147/jhc.s481393
2024-10-22
Journal of Hepatocellular Carcinoma
Abstract:Shang-Yu Lu, 1, &ast Han-Yao Sun, 1, &ast Yan Zhou, 2 Xi Luo, 3 Sheng Liu, 1 Wei-Zhong Zhou, 1 Hai-Bin Shi, 1 Wei Yang, 1 Wei Tian 1 1 Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; 2 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China; 3 The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Yang; Wei Tian, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, 210029, People's Republic of China, Tel +86-18705164897 ; +86-13770615508, Email ; Purpose: Hepatocellular carcinoma (HCC) represents a significant global health problem, requiring precise prognostic tools for optimal treatment stratification. This study aimed to develop a new risk prediction score, called AD score, based on the serum markers alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), to offer an objective and accurate preoperative assessment of HCC in patients undergoing transarterial chemoembolization (TACE). Patients and Methods: This was a retrospective study that included 295 HCC patients who were subjected to TACE (training set, n=147; testing set, n=148). Serum AFP and DCP levels were log-transformed to construct the AD score. Multivariate Cox regression analysis on cirrhosis subgroups validated the objectivity of the model. Performance comparison of established models (Child Pugh, BCLC, ALBI, Up-to-seven, Six-and-twelve, Four and seven, HAP score, mHAP-II, FAIL-T score), was assessed through time-dependent receiver operating characteristic (ROC) curves and risk stratification. Results: The AD score, incorporating lgAFP and lgDCP, demonstrated superior predictive accuracy than the existing models. Time-dependent ROC curve revealed the consistent superiority of the AD score over a 5-year period. The risk stratification into low, intermediate, and high group based on the AD score showed a significant survival difference in both training and testing set. Conclusion: For HCC patients undergoing TACE, the AD score serves as an objective and straightforward prognostic tool, enhancing predictive accuracy and showcasing its clinical utility. It demonstrates potential significance as a crucial addition to preoperative risk assessment for TACE. Keywords: hepatocellular carcinoma, transarterial chemoembolization, prognostic model, risk assessment, AD score Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the third leading cause of cancer-related death globally. 1,2 Transarterial chemoembolization (TACE) is widely recognized as one of the most commonly used treatments for HCC. According to the Barcelona Clinic Liver Cancer prognosis (BCLC) guidelines, surgical treatment is not suitable for patients with advanced HCC. For these patients, systemic therapy and TACE are the available treatment options. 3,4 However, the clinical practice revealed that not all individuals may equally benefit from TACE due to the difference in liver function and tumor burden. 5–7 Therefore, an accurate preoperative tumor staging is essential to identify the appropriate treatment and evaluate the prognosis in patients with HCC. 8,9 The main methods to evaluate the prognosis of TACE-treated patients in clinical practice are divided into two categories: those focusing on liver function, such as Child-Pugh and ALBI scores, 10 and those targeting tumor burden, including Up-to-seven and Six-and-twelve scores. 11,12 Although these staging methods predict the prognosis of HCC patients undergoing TACE to some extent, the discrepancy between liver function and tumor progression is evident. The complexity of tests also presents certain obstacles for clinical application. Therefore, an objective and simple method is needed to accurately predict the prognosis of patients undergoing TACE treatment. Currently, few reports are available on the combined use of common tumor markers in clinical practice for the preoperative assessment of HCC patients undergoing TACE. In clinical, The two major tumor markers for the preoperative assessment of liver cancer are alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP). 13 They respectively reflect tumor burden and liver function status. Additionally, DCP is also associated with hepatic insufficiency. It is undeniable that a significant survival difference exists between patients with hi -Abstract Truncated-
oncology